Verardi
Francesco Verardi, Douglas GB
Patent application number | Description | Published |
---|---|---|
20090149243 | Multi-level wager games with autocomplete - Multi-level wager games are described in which play at higher levels in the game continues even if the player does not achieve a winning result for play at a given level. Such play at the higher levels may be completed automatically in an autocomplete mode, without any additional player interaction. A payout is awarded if the outcome of play at any of the higher levels is a winning result in accordance with a special pay table designed for such autocomplete mode. In one embodiment, the special pay table is constructed such that the odds of obtaining a winning result in the autocomplete mode are less than the odds of obtaining a winning result for play at the first level. For example, in a two level poker game, if the player loses in the first level with only a pair of sixes (pair of Jacks or better needed for a winning hand in the first level), the cards in the second hand are revealed and the player obtains a winning result for second level hand only if the hand is dealt a Royal Flush. | 06-11-2009 |
20110045897 | Promotion Administration System and Method - A system for administering promotions in which a player is awarded promotion credit to be consumed in wagering activities includes a credit administration facility that maintains a player credit account, and a display means capable of displaying a composition of the player credit account on a display means. The promotion credit is either one or both of a priori and a posteriori promotion credit. The credit administration facility automatically determines the composition of the player credit account as a function of any credit purchases made by the player, wagers made by the player and their corresponding payouts, and any promotion credit awarded to the player. | 02-24-2011 |
Paulo Henrique Verardi, Mansfield Center, CT US
Patent application number | Description | Published |
---|---|---|
20130171189 | INDUCIBLE AND REPRESSIBLE VACCINIA VIRUSES WITH IMPROVED SAFETY - Described herein are recombinant vaccinia viruses that provide the efficacy of the current smallpox vaccine, but with a built-in safety mechanism, giving the physician or vaccine recipient (vaccinee) control over the vaccine virus replication. Specifically, genetic elements of the tetracycline (tet) operon and modified tet repressor genes are used to control the expression of vaccinia virus genes that are essential for viral replication, thereby allowing replication of the virus to be accurately regulated through the addition or removal of antibiotics (tetracyclines). The recombinant vaccinia viruses can be used as safer next-generation smallpox vaccines, as expression vectors for exogenous genes such as those encoding therapeutic or toxic proteins, as oncolytic viruses, and for tumor imaging and vector tracking in vivo. | 07-04-2013 |
Raffaello Verardi, Minneapolis, MN US
Patent application number | Description | Published |
---|---|---|
20140187615 | THERAPEUTIC POLYNUCLEOTIDES, COMPOSITIONS, AND METHODS - This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment. If treatment with the first xNA results in more myocyte relaxation than is desired, then the predetermined length of the second xNA molecule is shorter than the predetermined length of the first xNA. If, on the other hand, treatment with the first xNA results in less myocyte relaxation than is desired then the predetermined length of the second xNA molecule is longer than the predetermined length of the first xNA. | 07-03-2014 |